Project Grant R21CA291898
Award Date
7/18/24
Completion Date
6/30/26
Dollars Obligated
$433K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Evanston, IL 60201, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $714,317 to the Icahn School of Medicine at Mount Sinai to conduct research on the tumor microenvironment and mechanisms driving prostate cancer progression to metastatic castration-resistant disease. The research aims to: Determine how epithelial-mesenchymal transition (EMT) and mesenchymal-epithelial transition (MET) signaling within the tumor microenvironment impact anoikis...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $571,271 to the University of Texas Health Science Center at Houston to develop a targeted therapy for the treatment of metastatic castration-resistant prostate cancer (MCRPC). The research aims to synthesize a prostate-specific membrane antigen (PSMA)-targeted drug conjugate that can selectively deliver the microtubule inhibitor cryptophycin to MCRPC tumors. The project will...
The National Cancer Institute (NCI) awarded a $107,948 Project Grant to The Johns Hopkins University to conduct research on comparative analysis of M-CSF and GM-CSF in human monocyte metabolic reprogramming and differentiation into tumor-associated macrophage-like cells. The project, funded under CFDA 93.398 Cancer Research Manpower, aims to characterize differences in tumor-associated macrophage (TAM) functional attributes and their regulation between M-CSF and GM-CSF, as well as investigate...
This Project Grant award of $147,486 from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) supports research at the University of Pittsburgh to investigate the role of altered lipid metabolism in CD8 T cell exhaustion within the tumor microenvironment. The project aims to (1) evaluate the impact of abolishing citrate transport on carbon utilization and effector function of CD8 T cells in the tumor environment, and (2) determine the role of stored lipids in CD8 T cell...
The National Cancer Institute (NCI), under the Federal Grant Program "Cancer Research Manpower" (CFDA 93.398), awarded a Project Grant in the amount of $145,336 to the Sloan-Kettering Institute for Cancer Research located in New York. The grant, titled "Metabolically Reprogramming Hepatic Macrophages to Conquer Immune Desert Tumors," will fund research focused on reprogramming hepatic macrophages to overcome the "immune-desert" phenotype of B-catenin-driven...
The National Cancer Institute (NCI), under the federal Cancer Research Manpower Grant Program (CFDA 93.398), awarded a $159,304 Project Grant to the Dana-Farber Cancer Institute, Inc. (DFCI) located in Boston, Massachusetts. The grant aims to identify novel regulators of live cell phagocytosis by macrophages and determine the extent to which this process can destroy tumor cells in vivo. The research will focus on defining the role of deubiquitinases in regulating macrophage surface receptors...
This $169,776 Project Grant award from the National Cancer Institute's (NCI) Cancer Research Manpower program (CFDA 93.398) supports research by the Fred Hutchinson Cancer Center in Seattle, Washington to investigate mechanisms of immunotherapy resistance in prostate cancer bone metastases. The key products and services to be delivered include: Utilizing mouse models and patient bone biopsies to determine if a specific granulocyte subset (CD62LhiCXCR2hi-Gran) mediates immunotherapy resistance...
This Project Grant award from the National Cancer Institute (CFDA 93.396, Cancer Biology Research) aims to investigate key transcriptional regulators that drive prostate cancer lineage plasticity, which can lead to more lethal cancer subtypes. The $509,246 award to the Regents of the University of Michigan will fund a 5-year research project to: 1) determine how these transcriptional regulators modulate prostate cancer cell differentiation and hallmarks, 2) understand how the regulators are...
This $351,131 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by the University of Miami to mechanistically dissect the signaling interactions between myeloid-derived suppressor cells (MDSCs) and cancer-associated fibroblasts (CAFs) that contribute to chemotherapy and immunotherapy resistance in pancreatic ductal adenocarcinoma (PDAC). The goal is to uncover novel insights into the tumor-permissive and tolerogenic role of...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $415,902.00 to the University of Massachusetts Boston to conduct research aimed at overcoming lineage plasticity and therapy resistance in castration-resistant prostate cancer. The key research objectives are to determine if expression of the FOXA2 transcription factor drives prostate cancer cells into a multilineage transition state, investigate how FOXA2 collaborates with the AP-1...